AVTE Bathi resik saben saham sajrone 12 wulan pungkasan Aerovate Therapeutics Inc.

Tandha merek Aerovate Therapeutics (AVTE)

Aerovate Therapeutics (AVTE) develops inhalation therapies to combat pulmonary hypertension, focusing on rare pathologies. The trailing 12-month EPS reflects profit dynamics, with the value holding at -1.70. Patent protection and orphan drug status create barriers for competitors, although failed trials have led to workforce reductions and a speculative business valuation.

AVTE (aerovatetx.com) riwayat Bathi resik saben saham (EPS TTM) saka 04.07.2022 nganti 29.04.2025

Rincian analitis lan laporan data perusahaan Aerovate Therapeutics (AVTE)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:Aerovate Therapeutics - AVTE
Produk sing diprodhuksi Aerovate Therapeutics, Inc

Aerovate Therapeutics (AVTE) is stagnating due to the cessation of its primary clinical trials. The current TTM net income per share, equal to -1.70, reflects the trailing twelve-month equity profit adjusted for the number of shares. This metric measures the actual efficiency of capital generation per share. The flat trajectory of the TTM net income per share confirms a lack of commercial growth, and the business's fundamental stability is approaching zero.